Pharmaron Beijing Co., Ltd. (SHE:300759)
China
· Delayed Price · Currency is CNY 29.75
-1.17 (-3.78%)
Apr 29, 2026, 3:04 PM CST
Pharmaron Beijing Revenue
Pharmaron Beijing had revenue of 3.58B CNY in the quarter ending March 31, 2026, with 15.48% growth. This brings the company's revenue in the last twelve months to 14.57B, up 14.73% year-over-year. In the year 2025, Pharmaron Beijing had annual revenue of 14.10B with 14.82% growth.
Revenue (ttm)
14.57B
Revenue Growth
+14.73%
P/S Ratio
3.59
Revenue / Employee
580.94K
Employees
25,088
Market Cap
52.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.10B | 1.82B | 14.82% |
| Dec 31, 2024 | 12.28B | 737.78M | 6.39% |
| Dec 31, 2023 | 11.54B | 1.27B | 12.39% |
| Jan 1, 2023 | 10.27B | 2.82B | 37.92% |
| Dec 31, 2021 | 7.44B | 2.31B | 45.00% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Beijing Wantai Biological Pharmacy Enterprise | 1.82B |
| Sunshine Guojian Pharmaceutical (Shanghai) | 4.32B |
| Asymchem Laboratories (Tianjin) | 6.67B |
| Shanghai Allist Pharmaceuticals | 5.67B |
| Haisco Pharmaceutical Group | 5.06B |
| Hebei Changshan Biochemical Pharmaceutical | 928.01M |
| Shanghai RAAS Blood Products | 7.35B |
| Chongqing Zhifei Biological Products | 10.91B |